Shamburg News · 8-K filed Oct 2, 2026, 8:18 AM EDT
Century Therapeutics Presents Nonclinical CNTY-813 Data at EASD 2026
IPSC · Century Therapeutics, Inc.
- Other event
- Reg FD disclosure
- Materiality: low
On October 2, 2026, Century Therapeutics, Inc. issued a press release and posted presentation slides reporting nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, presented at the EASD meeting in Milan. The data showed sustained glycemic control in diabetic mice until graft removal and consistent product across five clinical-scale batches. The company stated its CNTY-813 IND submission remains on track for the fourth quarter of 2026, with initial clinical data anticipated in the second half of 2027.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001104659-26-113055.
Written from the filing by Shamburg Markets. Figures are as reported by the company.